 | |
| Clinical data | |
|---|---|
| Trade names | Oxilan |
| AHFS/Drugs.com | FDA Professional Drug Information |
| Routes of administration | intravenously |
| ATC code | |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | N/A |
| Protein binding | negligible |
| Metabolism | none |
| Eliminationhalf-life | 2 hours |
| Excretion | Mostlyrenal |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C18H24I3N3O8 |
| Molar mass | 791.116 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Ioxilan is a diagnosticcontrast agent.[1] It is injectedintravenously before takingX-ray images to increasearterial contrast in the final image. It was marketed in the US under the trade nameOxilan byGuerbet, L.L.C., but was discontinued in 2017.[2]
Ioxilan is aniodinated contrast agent.[2]
 | Thispharmacology-related article is astub. You can help Wikipedia byexpanding it. |
